Table 3.
Details of CD4 count categories
| Study name | Study type | Period | Diseases | Location | Study size | Follow up | CD4 (group 1) cells/mm3 | CD4(group 2) cells/mm3 | RR | 95% |
|---|---|---|---|---|---|---|---|---|---|---|
| Deti, 2010 | Cohort | 2004-2008 | CRF | France | 2613 | 3.4 | < 200 | > 500 | 4.04 | 2.3, 7.1 |
| Deti, 2010 | Cohort | 2004-2008 | CRF | France | 2613 | 3.4 | 200-500 | > 500 | 1.33 | 0.81, 2.19 |
| Franceschini, 2006 | Cohort | 2000-2002 | ARF | USA | 705 | 3.0 | < 200 | > 200 | 4.70 | 2.5, 8.8 |
| Ganesan, 2010 | Cohort | 1986-2008 | CKD | USA | 4044 | 6.5 | < = 200 | > = 500 | 6.8 | 3.0, 15.5 |
| Ganesan, 2010 | Cohort | 1986-2008 | CKD | USA | 4044 | 6.5 | 201-349 | > = 500 | 4.3 | 2.3, 8.1 |
| Ganesan, 2010 | Cohort | 1986-2008 | CKD | USA | 4044 | 6.5 | 350-499 | > = 500 | 2.4 | 1.3, 4.6 |
| Franey, 2009 | Cohort | 2004-2007 | RI | South Africa | 2189 | -- | < 100 | > 100 | 1.4 | 1.07, 1.82 |
| Ibrahim, 2010 | Cohort | 1999-2008 | ARF | UK | 2556 | -- | 201-350 | > 350 | 1.56 | 0.97, 2.48 |
| Ibrahim, 2010 | Cohort | 1999-2008 | ARF | UK | 2556 | -- | 101-200 | > 350 | 2.08 | 1.11, 3.91 |
| Ibrahim, 2010 | Cohort | 1999-2008 | ARF | UK | 2556 | -- | 51-100 | > 350 | 6.38 | 3.18, 12.78 |
| Ibrahim, 2010 | Cohort | 1999-2008 | ARF | UK | 2556 | -- | 0-50 | > 350 | 10.29 | 5.11, 20.98 |
| Krawczyk, 2004 | Cohort | 1992-2002 | CRF | USA | 6361 | -- | < 200 | 200-349 | 4.3 | 2.1, 8.7 |
| Roe, 2008 | Cohort | 1998-2005 | ARF | UK | 2274 | 8.0 | < 100 | > 200 | 6.75 | 2.5, 18.3 |
| Roe, 2008 | Cohort | 1998-2005 | ARF | UK | 2274 | 8.0 | 100-199 | > 200 | 3.02 | 0.99, 9.13 |
| Szczech, 2002 | Cohort | 1994-1999 | RF | USA | 2057 | 4.5 | < = 200 | > 200 | 3.57 | 1.72, 7.14 |
| Wei, | Cohort | 1993-1997 | HIVAN | USA | 44 | 5.1 | < = 100 | > = 100 | 2.73 | 0.82, 9.14 |